Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC

INTRODUCTION: Randomized prospective studies on patients with metastatic non‐small‐cell lung cancers (NSCLCs) showed that anti‐programmed death‐1 (PD‐1) agents notably improved 2‐year overall survival (OS) rates, compared to docetaxel. NSCLC patients now receive nivolumab and irradiation, concurrent...

Descripción completa

Detalles Bibliográficos
Autores principales: Lesueur, Paul, Escande, Alexandre, Thariat, Juliette, Vauléon, Enora, Monnet, Isabelle, Cortot, Alexis, Lerouge, Delphine, Danhier, Serge, Dô, Pascal, Dubos‐Arvis, Catherine, Chouaïd, Christos, Gervais, Radj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247050/
https://www.ncbi.nlm.nih.gov/pubmed/30311424
http://dx.doi.org/10.1002/cam4.1825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247050/
https://www.ncbi.nlm.nih.gov/pubmed/30311424
http://dx.doi.org/10.1002/cam4.1825

Ejemplares similares